This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of CymaBay's seladelpar, a peroxisome proliferator-activated receptor, in development for primary biliary cholangitis

Ticker(s): CBAY

Who's the expert?

Institution: Southern California Liver Centers

  • Hepatologist at Southern California Liver Centers ; formerly Professor of Medicine and Chief of Hepatology at Emory University.
  • Manages 25 patients with Primary biliary cirrhosis; specializes in liver diseases, including transplantation, and is an authority on drug-induced liver disease, HCV, NASH, and HBV.
  • Has served on an FDA advisory board evaluating new drugs for hepatology and is actively involved in a number of research studies, including the treatment of hepatitis C and B and non-alcoholic steatohepatitis.

Interview Questions

Can you please provide a brief introduction of your current practice, incorporating how many patients you treat from PBC?

Added By: sara_admin

What is the current standard of care and treatment options for your patients with PBC?

Added By: sara_admin

What are your initial thoughts on seladelpar and the ENHANCE studies' data?

Added By: sara_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.